I disagree, I think it's an excellent strategic move which, if we can get regulatory approval - will allow CPH to break in to a huge new market that most other ASX cannabis stocks currently do not have access to.
Viewing this opportunity as a "new illegal drug business pathway" is the rigid, 1970s type of mindset that had cannabis blacklisted as a gateway drug to begin with. This opportunity broadens our addressable market considerably. Alternative therapies for mental health, PTSD should not be underestimated as a potential market.
We're on track for record sales this year and aggressively establishing supply agreements and partnerships, however I do see the concern regarding high rate of cash burn. At the end of the day it's up to the individual SH to determine whether or not they want to invest long term or not, but that's where the money is going to be. Long termers will be rewarded IMHO.
- Forums
- ASX - By Stock
- CPH
- Ann: Creso to Acquire Psychedelics Company, Halucenex
Ann: Creso to Acquire Psychedelics Company, Halucenex, page-24
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CPH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online